Published in Pharmacogenomics J on January 01, 2004
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer (2007) 1.61
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol (2010) 1.55
Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia (2010) 1.36
Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res (2009) 1.25
Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer (2010) 1.05
Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum Genet (2006) 1.00
Clinical and pharmacogenomic implications of genetic variation in a Southern Ethiopian population. Pharmacogenomics J (2014) 0.89
Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer (2009) 0.83
Novel SNP improves differential survivability and mortality in non-small cell lung cancer patients. BMC Genomics (2014) 0.81
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat (2013) 0.81
Human cytidine deaminase: a biochemical characterization of its naturally occurring variants. Int J Biol Macromol (2013) 0.80
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Invest New Drugs (2010) 0.77
Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine. Pharmacogenet Genomics (2014) 0.77
Genetic polymorphisms of XPD and CDA and lung cancer risk. Oncol Lett (2012) 0.77
Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management. Pharmgenomics Pers Med (2010) 0.77
Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells. BMC Genomics (2016) 0.75
Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Int J Toxicol (2014) 0.75
Analysis of pharmacogenomic variants associated with population differentiation. PLoS One (2015) 0.75
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
COPD prevalence in a random population survey: a matter of definition. Eur Respir J (2007) 2.97
Risk of venous thromboembolism in users of hormone replacement therapy. Lancet (1996) 2.92
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
IMGT, the international ImMunoGeneTics database. Nucleic Acids Res (1997) 2.43
Structure of mitochondrial aldehyde dehydrogenase: the genetic component of ethanol aversion. Structure (1997) 2.38
Antagonist discrimination between ganglionic and ileal muscarinic receptors. Br J Pharmacol (1980) 2.31
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest (1996) 2.02
Quality of life measured by the St George's Respiratory Questionnaire and spirometry. Eur Respir J (2009) 1.99
The stereochemistry of the hydrogen elimination in the biological conversion of cholest-7-en-3-beta-ol into cholesterol. Biochem J (1967) 1.98
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta (2002) 1.98
Axonal GABA-receptors in mammalian peripheral nerve trunks. Brain Res (1978) 1.97
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther (2013) 1.94
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol (2013) 1.77
The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics (1999) 1.76
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics (2001) 1.70
Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg (2003) 1.59
Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis (2003) 1.59
Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst (2000) 1.57
Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther (2008) 1.54
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med (1998) 1.50
Recommendations for locus-specific databases and their curation. Hum Mutat (2008) 1.49
Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer (2002) 1.49
Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med (1999) 1.48
Laser capture microscopy. Mol Pathol (2000) 1.43
Mutations at codon 974 of the DPYD gene are a rare event. Br J Cancer (1997) 1.42
Reduction of polypharmacy by feedback to clinicians. J Gen Intern Med (1991) 1.41
Measles immunisation. Aust J Public Health (1992) 1.38
Ifosfamide-induced hyperpigmentation. Cancer (1993) 1.38
Detection of disease-specific PrP in the distal ileum of cattle exposed orally to the agent of bovine spongiform encephalopathy. Vet Rec (2003) 1.37
A very simple method for recording ganglion depolarization. J Physiol (1975) 1.36
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35
Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics (1999) 1.34
Current concepts in the development of heterotopic ossification. J Bone Joint Surg Br (2004) 1.32
Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics (1998) 1.30
Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet (1993) 1.29
Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer (2001) 1.29
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther (2007) 1.28
Three-dimensional structure of mammalian casein kinase I: molecular basis for phosphate recognition. J Mol Biol (1996) 1.26
Indirect effects of amino-acids on sympathetic ganglion cells mediated through the release of gamma-aminobutyric acid from glial cells. Br J Pharmacol (1976) 1.25
Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther (2001) 1.24
Comparative genomic hybridization and chromosomal instability in solid tumours. Br J Cancer (1999) 1.24
Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics (2000) 1.24
Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med (2000) 1.23
Studies on the regulation of the mitochondrial alpha-ketoacid dehydrogenase complexes and their kinases. Adv Enzyme Regul (1997) 1.23
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost (2009) 1.22
Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet (1999) 1.19
Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol (1996) 1.18
Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res (2001) 1.18
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther (2007) 1.16
Human liver mitochondrial aldehyde dehydrogenase: three-dimensional structure and the restoration of solubility and activity of chimeric forms. Protein Sci (1999) 1.12
PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep (2007) 1.11
Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer (2001) 1.09
Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol (2001) 1.09
Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol (2001) 1.08
Lessons learned from the irinotecan metabolic pathway. Curr Med Chem (2003) 1.08
Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer (2000) 1.08
Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? Eur J Cancer (2000) 1.08
Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal. Neurotoxicology (2006) 1.07
Physical linkage of the fragile site FRA11B and a Jacobsen syndrome chromosome deletion breakpoint in 11q23.3. Hum Mol Genet (1994) 1.07
Application of laser capture microdissection and proteomics in colon cancer. Mol Pathol (2001) 1.07
Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors. Cancer Res (1998) 1.06
Catalytic efficiency of human alcohol dehydrogenases for retinol oxidation and retinal reduction. Alcohol Clin Exp Res (1994) 1.06
Population variation in VKORC1 haplotype structure. J Thromb Haemost (2006) 1.05
Primary pulmonary osteosarcoma: case report and molecular analysis. Cancer (2001) 1.05
Colorectal cancer genomics: evidence for multiple genotypes which influence survival. Br J Cancer (2001) 1.04
Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res (2001) 1.04
Hydrolysis of capecitabine to 5'-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J Pharmacol Exp Ther (2005) 1.03
Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J (2007) 1.03
General base catalysis in a glutamine for histidine mutant at position 51 of human liver alcohol dehydrogenase. Biochemistry (1991) 1.03
Novel thymidylate synthase enhancer region alleles in African populations. Hum Mutat (2000) 1.03
Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. Oncol Rep (2001) 1.03
The potential roles of the conserved amino acids in human liver mitochondrial aldehyde dehydrogenase. J Biol Chem (1997) 1.03
Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer (1998) 1.02
Cancer pharmacogenetics. Br J Cancer (2004) 1.01
Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res (1999) 1.01
Expression and kinetic characterization of recombinant human stomach alcohol dehydrogenase. Active-site amino acid sequence explains substrate specificity compared with liver isozymes. J Biol Chem (1995) 1.00
Ethnic differences in pharmacogenetically relevant genes. Curr Drug Targets (2006) 1.00
Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. Clin Cancer Res (2000) 0.99
Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics (2001) 0.99
c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer (2002) 0.99
Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther (2000) 0.98
Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest (1993) 0.98
Angiotensin mimics the action of muscarinic agonists on rat sympathetic neurones. Brain Res (1980) 0.97
Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice. Pharmacogenomics J (2010) 0.97
Kinetic mechanism of human glutathione-dependent formaldehyde dehydrogenase. Biochemistry (2000) 0.96
Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol (2002) 0.96
Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. Br J Cancer (2005) 0.96
Childhood asthma and GOLD-defined chronic obstructive pulmonary disease. Intern Med J (2010) 0.95
X-ray structure of human class IV sigmasigma alcohol dehydrogenase. Structural basis for substrate specificity. J Biol Chem (1997) 0.94